Quest product, Lintor, to help diabetes treatment in Nepal
Kathmandu, April 10, 2017:
A common ailment, diabetes affects nearly 400 million people worldwide. Quest Pharmaceuticals today launched the latest medication, Lintor, to provide relief to diabetes patients in Nepal.
“Diabetes affects nearly 19% of Nepal’s population. Patients suffering from this disease are unable to regulate blood glucose (sugar) leading to general fatigue and blurred vision among others. Lintor is a potent hypoglycemic agent that effectively addresses diabetes,” said S.P.Verma, Director Marketing, Quest Pharmaceuticals P. Ltd.
A genetically-transmitted disease, diabetes is known to aggravate with static urban lifestyles. Lintor, available in dosage of 2.5 mg and 5 mg tablets, helps body produce more insulin to regulate blood sugar.
“Many illnesses including diabetes can be controlled with healthy lifestyles. Along with physical exercise, Lintor will help patients’ lead healthier lives,” S.P.Verma added.
Lintor is available at all leading medical stores across the country.